Betulinaldehyde Ameliorates Aβ-Induced Neurotoxicity and Cognitive Deficits by Modulating the eEF2K/eEF2 Pathway

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) lacks effective treatments, with the eEF2K/eEF2 pathway implicated in neuronal dysfunction.
• Limited pharmacological options exist to target the eEF2K/eEF2 pathway in AD.
• Betulinaldehyde (Betu), a compound from traditional Chinese medicine, requires evaluation for neuroprotective potential.

Purpose of the Study:

• To investigate the therapeutic effects of Betu on AD.
• To determine if Betu's effects are mediated via the eEF2K/eEF2 pathway.

Main Methods:

• Neuronal cell models assessed Betu's impact on Aβ42-induced toxicity, protein synthesis, and eEF2 phosphorylation.
• eEF2K activators and protein synthesis inhibitors were used to probe pathway involvement.
• Cellular thermal shift assay (CETSA) explored Betu-eEF2K interaction.
• Aβ42-induced AD mouse models evaluated cognitive and neuropathological outcomes.

Main Results:

• Betu counteracted Aβ42-induced neuronal death, dendritic spine damage, and protein synthesis inhibition.
• Betu reversed eEF2 hyperphosphorylation, with effects blocked by pathway inhibitors.
• CETSA indicated Betu interacts with eEF2K.
• Betu reduced oxidative stress and modulated downstream pathways (NRF2/HO-1).
• In vivo, Betu improved cognition and reduced neuropathology in an AD mouse model.

Conclusions:

• Betu demonstrates neuroprotection against Aβ42-induced toxicity by modulating the eEF2K/eEF2 pathway.
• Betu shows promise as a lead compound for developing Alzheimer's disease therapies.